VIGIL NEUROSCIENCE INC(NASDAQ:VIGL) stock Fundamental Analysis

Fundamental Rating

VIGL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. While VIGL seems to be doing ok healthwise, there are quite some concerns on its profitability. VIGL is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

VIGL had negative earnings in the past year.

VIGL had a negative operating cash flow in the past year.

VIGL had negative earnings in each of the past 5 years.

VIGL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

VIGL has a Return On Assets of -71.59%. This is in the lower half of the industry: VIGL underperforms 64.46% of its industry peers.

With a Return On Equity value of -117.62%, VIGL perfoms like the industry average, outperforming 41.96% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-71.59%
ROE	-117.62%
ROIC	N/A

ROA(3y)-54.78%

ROA(5y)-63.89%

ROE(3y)-74.94%

ROE(5y)-84.7%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VIGL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VIGL has more shares outstanding than it did 1 year ago.

VIGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

VIGL has an Altman-Z score of -0.69. This is a bad value and indicates that VIGL is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of VIGL (-0.69) is better than 62.14% of its industry peers.

VIGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.69

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

VIGL has a Current Ratio of 2.95. This indicates that VIGL is financially healthy and has no problem in meeting its short term obligations.

VIGL's Current ratio of 2.95 is on the low side compared to the rest of the industry. VIGL is outperformed by 65.18% of its industry peers.

VIGL has a Quick Ratio of 2.95. This indicates that VIGL is financially healthy and has no problem in meeting its short term obligations.

VIGL has a Quick ratio of 2.95. This is in the lower half of the industry: VIGL underperforms 63.93% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.95
Quick Ratio	2.95

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

VIGL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.30%.

EPS 1Y (TTM)3.3%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%2%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

VIGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.11% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y10.58%

EPS Next 2Y7.92%

EPS Next 3Y6.53%

EPS Next 5Y20.11%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIGL. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIGL. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y7.92%

EPS Next 3Y6.53%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VIGL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIGIL NEUROSCIENCE INC

NASDAQ:VIGL (5/29/2025, 9:42:45 AM)

7.885

0 (-0.06%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-07 2025-05-07/bmo

Earnings (Next)N/A N/A

Inst Owners77.91%

Inst Owner Change9.5%

Ins Owners12.85%

Ins Owner Change0.74%

Market Cap367.99M

Analysts88.57

Price Target15.74 (99.62%)

Short Float %0.83%

Short Ratio2.25

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)4.87%

Min EPS beat(2)-5.67%

Max EPS beat(2)15.41%

EPS beat(4)3

Avg EPS beat(4)9.04%

Min EPS beat(4)-5.67%

Max EPS beat(4)19.09%

EPS beat(8)6

Avg EPS beat(8)6.68%

EPS beat(12)10

Avg EPS beat(12)8.39%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-2.81%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-6.28%

EPS NY rev (1m)8.99%

EPS NY rev (3m)8.78%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	5.14
P/tB	5.14
EV/EBITDA	N/A

EPS(TTM)-2.05

EYN/A

EPS(NY)-1.72

Fwd EYN/A

FCF(TTM)-1.1

FCFYN/A

OCF(TTM)-1.1

OCFYN/A

SpS0

BVpS1.53

TBVpS1.53

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-71.59%
ROE	-117.62%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-54.78%

ROA(5y)-63.89%

ROE(3y)-74.94%

ROE(5y)-84.7%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1.1%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.95
Quick Ratio	2.95
Altman-Z	-0.69

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)440.01%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)3.3%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%2%

EPS Next Y10.58%

EPS Next 2Y7.92%

EPS Next 3Y6.53%

EPS Next 5Y20.11%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-0.92%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-33.05%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y27.89%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y27.2%

OCF growth 3YN/A

OCF growth 5YN/A

VIGIL NEUROSCIENCE INC (VIGL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens